Business
Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets
Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman for human indications of crofelemer approved in the U.S., including future target indicationsSAN FRANCISCO, CA / ACCESSWIRE / March 31, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company has entered an agreement (the \"Agreement\") with Quadri Pharmaceuticals Store LLC (Quadri Pharma) that grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for specified human indications of crofelemer in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates (UAE), and Oman following regulatory approval to market crofelemer in these countries for the specified indications, including the indication currently approved in the U.S. for HIV-related diarrhea, and cancer therapy-related diarrhea, for which crofelemer is currently in a pivotal Phase 3 clinical trial. In addition, the Agreement grants Quadri Pharma exclusive rights to distribute crofelemer in these countries in the immediate future under Named Patient Programs.According to the UNAIDS 2020 global report, the HIV epidemic is growing in the Middle East and North Africa (MENA) region, with an estimated 20,000 new infections in 2019 - a 25% increase over new infections in 2010, and an estimated 170,000 to 400,000 adults and children in the region lived with HIV in 2019. Data from this report indicates that 52% of people living with HIV in the MENA region knew their status in 2019, 38% were accessing antiretroviral therapy, and less than one third were virally suppressed.1\"Our collaboration with Quadri Pharma is a welcome and important step towards making crofelemer's novel mechanism of action available to patients in need in global markets,\" said Karen Brunke, PhD, Jaguar Health's Executive Vice President of Corporate and Business Development. \"We look forward to a close relationship with Quadri Pharma and their team of experienced professionals.\"Crofelemer is Jaguar Health's antidiarrheal drug product that is approved, under the name Mytesi (crofelemer 125 mg delayed-release tablets), in the U.S. by the U.S. Food and Drug Administration for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral...